Page last updated: 2024-12-07

mannuronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

mannuronic acid: hydrolysis product of alginic acids from ALGAE; has anti-inflammatory activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

D-mannopyranuronic acid : The pyranose form of D-mannonic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439630
CHEBI ID79047
SCHEMBL ID3178574
MeSH IDM0052057

Synonyms (20)

Synonym
C02024
d-mannuronate
d-mannuronic acid
(2s,3s,4s,5s)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid
mannuronic acid
SCHEMBL3178574
CHEBI:79047 ,
d-mannopyranuronic acid
mannopyranuronate
mannuronate ,
MANA ,
d-mannopyranuronate ,
mannopyranuronic acid
d-mana
(2s,3s,4s,5s)-3,4,5,6-tetrahydroxytetrahydropyran-2-carboxylic acid
ag-g-68413
surecn3178574
EN300-20702255
2089580-74-3
dtxcid30140807

Research Excerpts

Toxicity

The incidence of gastrointestinal and other adverse events were higher on naproxen than on β-d-mannuronic acid and placebo. The study found no adverse effect on differentiation, maturation and function of dendritic cells.

ExcerptReferenceRelevance
"Our findings show that β-D-mannuronic acid (m2000) as a safe agent had no adverse effect on differentiation, maturation and function of dendritic cells which might be recommended as a novel immunosuppressive agent with no or fewer side effects in increasing the risk of infectious diseases and cancers."( The Safety Property of β-D-Mannuronic Acid (M2000) as a Novel Immunosuppressive Agent on Differentiation, Maturation and Function of Human Dendritic Cells.
Fard, NA; Mirshafiey, A; Mirzaei, R; Motamed, N; Tabrizian, N; Zavareh, FT, 2016
)
0.43
" The incidence of gastrointestinal and other adverse events were higher on naproxen than on β-d-mannuronic acid and placebo."( Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial.
Aghazadeh, Z; Ahmadi, H; Cuzzocrea, S; Fattahi, MJ; Hashemi, SN; Hosseini, M; Jafarnezhad-Ansariha, F; Jamshidi, AR; Mahmoudi, M; Matsuo, H; Mirshafiey, A; Rehm, BHA; Vojdanian, M; Yekaninejad, MS, 2018
)
0.48
"1% of conventional-treated patient's adverse events occurred during this study."( A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-D-mannuronic acid in rheumatoid arthritis patients.
Aghazadeh, Z; Ahmadi, H; Cuzzocrea, S; Fattahi, MJ; Gharibdoost, F; Hosseini, M; Jamshidi, AR; Mahmoudi, M; Matsuo, H; Mirshafiey, A; Mortazavi-Jahromi, SS; Mostafaei, S; Rastkari, N; Rehm, BHA; Vojdanian, M, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" In addition to the utilization as implantable cell reactors in therapy and biotechnology, these purified algins have broad application potential as ocular fillings, tissue replacements, microencapsulated growth factors and/or interleukins or slow-release dosage forms of antibodies, surface coatings of sensors and other invasive medical devices, and in encapsulation of genetically engineered cells for gene therapy."( Biocompatibility of mannuronic acid-rich alginates.
Gröhn, P; Hahn, HJ; Klöck, G; Kuttler, B; Pfeffermann, A; Ryser, C; Zimmermann, U, 1997
)
0.3
"Alginates are useful natural polymers suitable for use in the design of pharmaceutical dosage forms."( Evaluation of sodium alginate as drug release modifier in matrix tablets.
Chan, LW; Ching, AL; Heng, PW; Liew, CV, 2006
)
0.33
" Further fine tuning of alginate formulation and effective dosage for might be required in order to improve therapeutic efficacy depending on the target disease."( MSC encapsulation in alginate microcapsules prolongs survival after intra-articular injection, a longitudinal in vivo cell and bead integrity tracking study.
Bernsen, M; Bos, PK; Haeck, J; Khatab, S; Kops, N; Leijs, MJ; Nieboer, M; van Buul, G; van Osch, GJVM; Verhaar, JAN, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
D-mannonic acidThe D-stereoisomer of mannonic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (171)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (4.09)18.7374
1990's20 (11.70)18.2507
2000's38 (22.22)29.6817
2010's74 (43.27)24.3611
2020's32 (18.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (9.14%)5.53%
Reviews3 (1.71%)6.00%
Case Studies1 (0.57%)4.05%
Observational0 (0.00%)0.25%
Other155 (88.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]